Open AccessNo Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial
Author(s) -
Jonathan Z. Li,
Paul E. Sax,
Vincent C. Marconi,
Jesse Fajnzylber,
Baiba Berzins,
Amesika N. Nyaku,
Carl J. Fichtenbaum,
Timothy Wilkin,
Constance A. Benson,
Susan L. Koletar,
Ramon LorenzoRedondo,
Babafemi Taiwo
Publication year - 2019
Publication title -
open forum infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.546
H-Index - 35
ISSN - 2328-8957
DOI - 10.1093/ofid/ofz056
Subject(s) - dolutegravir , viremia , lamivudine , medicine , viral load , virology , randomization , antiretroviral therapy , residual , human immunodeficiency virus (hiv) , randomized controlled trial , pharmacology , virus , algorithm , hepatitis b virus , computer science
In the ASPIRE trial, antiretroviral therapy (ART) switch to dolutegravir plus lamivudine (DTG+3TC) was comparable to 3-drug ART in maintaining viral suppression by standard viral load assays. We used an ultrasensitive assay to assess whether this switch led to increased residual viremia. At entry, levels of residual viremia did not differ significantly between arms (DTG+3TC vs 3-drug ART: mean, 5.0 vs 4.2 HIV-1 RNA copies/mL; = .64). After randomization, no significant between-group differences were found at either week 24 or 48. These results show no evidence for increased viral replication on DTG+3TC and support its further investigation as a dual ART strategy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom